Stay updated on Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial

Sign up to get notified when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.2 to v3.8.0; the page content still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T16:18:58.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s terminology transition from “Artificial Intelligence” to “Super Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T19:12:49.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-18T22:36:06.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1 on the 403 Forbidden page; the study record remains unavailable.
    Difference
    0.2%
    Check dated 2026-10-11T22:28:26.000Z thumbnail image
  5. Check
    48 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content with a standard error page. This blocks access to the study details and related information on the page.
    Difference
    18%
    Check dated 2026-09-20T19:53:51.000Z thumbnail image
  6. Check
    69 days ago
    Change Detected
    Summary
    Revision label updated from v3.6.5 to v3.6.6, indicating a minor site version bump.
    Difference
    0.1%
    Check dated 2026-08-30T22:38:08.000Z thumbnail image

Stay in the know with updates to Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Benralizumab in Anti-IL5 Inadequate Responders Clinical Trial page.